FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016307324> ?p ?o ?g. }

• W2016307324 endingPage "9" @default.
• W2016307324 startingPage "1" @default.
• W2016307324 abstract "Background. The outcome of HIV-associated non-Hodgkin lymphoma (NHL) has improved substantially in the highly active antiretroviral therapy (HAART) era. However, HIV-Burkitt lymphoma (BL), which accounts for up to 20% of HIV-NHL, has poor outcome with standard chemotherapy. Patients and Methods. We retrospectively reviewed HIV-BL treated in the HAART era with the Magrath regimen (CODOX-M/IVAC±R) at four Canadian centres. Results. Fourteen patients with HIV-BL received at least one CODOX-M/IVAC±R treatment. Median age at BL diagnosis was 45.5 years, CD4 count 375 cells/mL and HIV viral load (VL) <50 copies/mL. Patients received PCP prophylaxis and G-CSF, 13 received HAART with chemotherapy and 10 rituximab. There were 63 episodes of toxicity, none fatal, including: bacterial infection, n = 20; grade 3-4 hematologic toxicity, n = 14; febrile neutropenia, n = 7; oral thrush; and ifosfamide neurological toxicity, n = 1 each. At a median followup of 11.7 months, 12 (86%) patients are alive and in remission. All 10 patients who received HAART, chemotherapy, and rituximab are alive. CD4 counts and HIV VL 6 months following BL therapy completion (n = 5 patients) were >250 cells/mL and undetectable, respectively, in 4. Conclusion. Intensive chemotherapy with CODOX-M/IVAC±R yielded acceptable toxicity and good survival rates in patients with HIV-associated Burkitt lymphoma receiving HAART." @default.
• W2016307324 created "2016-06-24" @default.
• W2016307324 creator A5000010395 @default.
• W2016307324 creator A5024269299 @default.
• W2016307324 creator A5040880676 @default.
• W2016307324 creator A5042821201 @default.
• W2016307324 creator A5060131877 @default.
• W2016307324 creator A5061369789 @default.
• W2016307324 creator A5061614395 @default.
• W2016307324 creator A5070115729 @default.
• W2016307324 creator A5071029042 @default.
• W2016307324 creator A5086115833 @default.
• W2016307324 date "2012-01-01" @default.
• W2016307324 modified "2023-10-13" @default.
• W2016307324 title "HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era" @default.
• W2016307324 cites W105359055 @default.
• W2016307324 cites W1561057994 @default.
• W2016307324 cites W1737297041 @default.
• W2016307324 cites W1783838151 @default.
• W2016307324 cites W1832431868 @default.
• W2016307324 cites W1875078190 @default.
• W2016307324 cites W1889566095 @default.
• W2016307324 cites W1902149439 @default.
• W2016307324 cites W1947622855 @default.
• W2016307324 cites W1963725804 @default.
• W2016307324 cites W1966831995 @default.
• W2016307324 cites W1975280591 @default.
• W2016307324 cites W1994542857 @default.
• W2016307324 cites W2009384883 @default.
• W2016307324 cites W2012963121 @default.
• W2016307324 cites W2021619016 @default.
• W2016307324 cites W2027030762 @default.
• W2016307324 cites W2027886447 @default.
• W2016307324 cites W2036379838 @default.
• W2016307324 cites W2038085891 @default.
• W2016307324 cites W2039104712 @default.
• W2016307324 cites W2058015212 @default.
• W2016307324 cites W2058106888 @default.
• W2016307324 cites W2068673954 @default.
• W2016307324 cites W2068707796 @default.
• W2016307324 cites W2070381192 @default.
• W2016307324 cites W2075947927 @default.
• W2016307324 cites W2079598348 @default.
• W2016307324 cites W2107089728 @default.
• W2016307324 cites W2115312840 @default.
• W2016307324 cites W2118221216 @default.
• W2016307324 cites W2129227196 @default.
• W2016307324 cites W2138030132 @default.
• W2016307324 cites W2145304413 @default.
• W2016307324 cites W2167267945 @default.
• W2016307324 cites W2335295875 @default.
• W2016307324 cites W4295934099 @default.
• W2016307324 doi "https://doi.org/10.1155/2012/735392" @default.
• W2016307324 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3235428" @default.
• W2016307324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22190945" @default.
• W2016307324 hasPublicationYear "2012" @default.
• W2016307324 type Work @default.
• W2016307324 sameAs 2016307324 @default.
• W2016307324 citedByCount "36" @default.
• W2016307324 countsByYear W20163073242012 @default.
• W2016307324 countsByYear W20163073242013 @default.
• W2016307324 countsByYear W20163073242014 @default.
• W2016307324 countsByYear W20163073242015 @default.
• W2016307324 countsByYear W20163073242016 @default.
• W2016307324 countsByYear W20163073242017 @default.
• W2016307324 countsByYear W20163073242018 @default.
• W2016307324 countsByYear W20163073242019 @default.
• W2016307324 countsByYear W20163073242020 @default.
• W2016307324 countsByYear W20163073242021 @default.
• W2016307324 countsByYear W20163073242022 @default.
• W2016307324 countsByYear W20163073242023 @default.
• W2016307324 crossrefType "journal-article" @default.
• W2016307324 hasAuthorship W2016307324A5000010395 @default.
• W2016307324 hasAuthorship W2016307324A5024269299 @default.
• W2016307324 hasAuthorship W2016307324A5040880676 @default.
• W2016307324 hasAuthorship W2016307324A5042821201 @default.
• W2016307324 hasAuthorship W2016307324A5060131877 @default.
• W2016307324 hasAuthorship W2016307324A5061369789 @default.
• W2016307324 hasAuthorship W2016307324A5061614395 @default.
• W2016307324 hasAuthorship W2016307324A5070115729 @default.
• W2016307324 hasAuthorship W2016307324A5071029042 @default.
• W2016307324 hasAuthorship W2016307324A5086115833 @default.
• W2016307324 hasBestOaLocation W20163073241 @default.
• W2016307324 hasConcept C126322002 @default.
• W2016307324 hasConcept C141071460 @default.
• W2016307324 hasConcept C143998085 @default.
• W2016307324 hasConcept C2776694085 @default.
• W2016307324 hasConcept C2777063308 @default.
• W2016307324 hasConcept C2778850193 @default.
• W2016307324 hasConcept C2779338263 @default.
• W2016307324 hasConcept C2780653079 @default.
• W2016307324 hasConcept C2781413609 @default.
• W2016307324 hasConcept C71924100 @default.
• W2016307324 hasConcept C90924648 @default.
• W2016307324 hasConceptScore W2016307324C126322002 @default.
• W2016307324 hasConceptScore W2016307324C141071460 @default.
• W2016307324 hasConceptScore W2016307324C143998085 @default.
• W2016307324 hasConceptScore W2016307324C2776694085 @default.

• next